Clinical Trial Update: Zanubrutinib for HLH [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for zanubrutinib in hemophagocytic lymphohistiocytosis (HLH) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: HLH | Phase 3 | Status: COMPLETED